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Abstract: Bladder cancer still requires improvements in diagnosis and prognosis, because many of
the cases will recur and/or metastasize with bad outcomes. Despite ongoing research on bladder
biomarkers, the clinicopathological impact and diagnostic function of miRNA maturation regulators
Drosha and Argonaute proteins AGO1 and AGO2 in urothelial bladder carcinoma remain unclear.
Therefore, we conducted immunohistochemical investigations of a tissue microarray composed of
112 urothelial bladder carcinomas from therapy-naïve patients who underwent radical cystectomy
or transurethral resection and compared the staining signal with adjacent normal bladder tissue.
The correlations of protein expression of Drosha, AGO1 and AGO2 with sex, age, tumor stage,
histological grading and overall survival were evaluated in order to identify their diagnostic and
prognostic potential in urothelial cancer. Our results show an upregulation of AGO1, AGO2 and
Drosha in non-muscle-invasive bladder carcinomas, while there was increased protein expression
of only AGO2 in muscle-invasive bladder carcinomas. Moreover, we were able to differentiate
between non-muscle-invasive and muscle-invasive bladder carcinoma according to AGO1 and
Drosha expression. Finally, despite Drosha being a discriminating factor that can predict the
probability of overall survival in the Kaplan–Meier analysis, AGO1 turned out to be independent of
all clinicopathological parameters according to Cox regression. In conclusion, we assumed that the
miRNA processing factors have clinical relevance as potential diagnostic and prognostic tools for
bladder cancer.
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1. Introduction
In 2012, 430,000 new cases of bladder cancer were diagnosed worldwide. Thus, bladder cancer
is the ninth most common cancer in the world with the highest incidence in Northern America,
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Europe and some countries in Northern Africa and Western Asia [1]. Despite their heterogeneity,
several characteristics have been found, which distinguish the subgroups of less aggressive, but often
recurring non-muscle-invasive bladder cancer (NMIBC) and the more progressive muscle-invasive
bladder cancer (MIBC). The latter holds an overall survival rate of 60% at most [2]. NMIBC develops
from urothelial hyperplasia to low-grade carcinoma, with up to 15% proceeding to high-grade tumors.
These cancers show characteristic alterations in the Ras-MAPK and PI3K-Akt pathways. The pathway
leading to MIBC often includes dysplasia/carcinoma in situ and high-grade non-invasive carcinoma
that accumulates common defects, e.g., in tumor suppressors, such as p53 or pRb, or in matrix
metalloproteinases [2,3]. Although several potential biomarkers have been tested for their diagnostic
and prognostic potential, targets for routine use are still needed.
A recent field of biomarker research has focused on microRNAs (miRNAs), which are involved
in various biological processes, including tumorigenesis [4,5]. Several studies profiled the miRNA
expression patterns in bladder cancer tissue and indicated some interesting findings regarding its
diagnostic and/or prognostic potential [6,7]. The biogenesis of miRNAs is a multistep process
involving a couple of protein complexes [8]. In the nucleus, miRNA genes are transcribed by
RNA polymerase II/III into a long single or multiple primary miRNA, which is subsequently
processed by the “Drosha microprocessor” into hairpin precursor miRNA (pre-miRNA). This “Drosha
microprocessor” is a complex of the RNase III enzyme Drosha, its cofactor DiGeorge syndrome critical
region gene 8 (DGCR8/Pasha) and other components. The pre miRNA is actively exported by exportin
5/Ras-related nuclear protein-guanosine triphosphate (Ran-GTP) to the cytoplasm. In this cellular
compartment, RNase III enzyme Dicer converts pre miRNA to a mature double-stranded miRNA
duplex that contains both the mature and its complementary strand and consists of about 20 nucleotides.
The mature miRNA is subsequently loaded onto the miRNA Induced Silencing Complex (miRISC).
The Argonaute (AGO) family proteins AGO1–AGO4 are the central components of the miRISC complex,
which stabilize the mature miRNA strand. The other strand is degraded. AGO2 is the only protein
with endonucleolytic activity that mediates the inhibition of target mRNA expression. The subsequent
rate of miRNA complementarity and target mRNA affects the repression of translation or cleavage
of mRNA. Additionally, there is some evidence indicating an alternative biogenesis pathway in
which pre miRNAs are directly loaded onto the miRISC complex after Drosha processing, omitting
Dicer processing [9].
As mentioned above, AGO1 and AGO2 are needed for the process of degrading mRNAs or
impairing their translation, while Drosha plays a role in initial miRNA maturation. Consequently,
it is postulated that they also play a key role in tumor behavior. Some studies have already reported
a tumor specific expression of AGO1, AGO2, Dicer and Drosha in the urogenital tract. For example,
the Argonautes have been implicated in clear cell renal cell carcinoma [10] and prostate cancer [11].
Meanwhile, the data for Argonautes and Drosha also exist for bladder carcinoma [12,13], but these are
contradictory to our findings in major points and require discussion. The aim of our comprehensive
immunohistochemical study was to investigate AGO1, AGO2 and Drosha expression in normal
bladder urothelium and malignant bladder cancer tissue (NMIBC and MIBC) using a tissue microarray
(TMA) as well as to correlate the expression of these proteins with clinicopathological parameters.
We believe that our findings will support the potential of these three targets to become bladder
carcinoma biomarkers but they will have to be carefully investigated further to avoid inaccurate
conclusions indicated by the contradictory results in the literature.
2. Results
2.1. Immunostaining Pattern of AGO1, AGO2, and Drosha Expression in Bladder Tissue
All three targets appeared with a granular pattern in malignant and non-malignant tissue,
while they were also often expressed in endothelial cells (Figures 1 and 2). AGO1 staining was
found in the cytoplasm and partly in the nuclei of normal and tumor tissue (Figure 1A–C). AGO2 was
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mainly expressed in the cytoplasm and particularly in the pseudoluminal areas of tumors and adjacent
normal tissue (Figure 1D–F). Furthermore, AGO2 was also found in lymphocytes (Figure 1F). Drosha
staining was located in the cytoplasm and partly in the nucleus in normal and tumor tissue (Figure 2).
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Figure 1. Immunohistochemical staining of AGO1 and AGO2 in bladder tissue. Representative 
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pT1 tumor (B) and muscle-invasive pT3b tumor tissue (C); as well as the expression of AGO2 in 
normal bladder tissue (D), in non-muscle-invasive pTa tumor (E) and muscle-invasive pT3b tumor 
tissue (F). The arrows indicate the staining in endothelial cells (A) and AGO2 staining of lymphocytes 
(F). Pseudoluminal expression of AGO2 can be seen in (D). Magnification: 200×, inserts 400×. 
Figure 1. I unohistoche ical staining of AGO1 and AGO2 in bladder tissue. Representative
i ages sho the expression of AGO1 in non-malignant bladder tissue (A), in non-muscle-invasive pT1
tumor (B) and muscle-invasive pT3b tumor tissue (C); as well as the expression of AGO2 in normal
bladder tissue (D), in non-muscle-invasive pTa tumor (E) and muscle-invasive pT3b tumor tissue
(F). The arrows indicate the staining in endothelial cells (A) and AGO2 staining of lymphocytes (F).
Pseudoluminal expression of AGO2 can be seen in (D). Magnification: 200×, inserts 400×.
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Figure 2. Immunohistochemical staining of Drosha in bladder tissue. Representative images show
the expression of Drosha in non-malignant bladder tissue (A), in non-muscle-invasive pT1 tumor
(B) and muscle-invasive pT3b tumor tissue (C). The staining of endothelial cells can be seen in (A).
Magnification: 200×, inserts 400×.
2.2. AGO1, AGO2 and Dr sha Expression in Bladder Carcinomas Compared to Non-Malignant Tissue and
Association with Clinicopathological Parameters
The clinicopathological parameters of the bla der cancer cases sh wn in Table 1. AGO1, AGO2
and Dr sha were markedly upregulated in NMIBC compared to adjacent normal tissue. However,
only AGO2 was significantly upregulated in MIBC (Table 2). Positive AGO2 staining identified 73/109
tumors (67%) without any difference between NMIBC and MIBC when calculating a Fisher’s exact
test (Table 3). However, AGO1 and Drosha expression was decreased in NMIBC compared to MIBC
(p < 0.001, Table 3).
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Table 1. Clinicopathological characteristics of the patients undergoing transurethral resection of the
bladder or radical cystectomy.
























Status after follow-up time C
alive 67 (60.9)
dead 43 (39.1)
A Age was dichotomized according to median; B WHO/ISUP criteria of 2016; C 110 cases available.
WHO: World Health Organization; ISUP: International Society of Uropathology; TUR-B: transurethral resection of
the bladder; RTX: radical cystectomy.
Table 2. Comparison of AGO1, AGO2, and Drosha expression in adjacent normal tissue to NMIBC as
well as MIBC in valid cases.
Characteristics Nonmalignant n (%) NMIBC n (%) MIBC n (%)
Argonaute 1 30 (100) 60 (100) 38 (100)
negative 22 (73.3) 23 (38.3) 30 (78.9)
positive 8 (26.7) 37 (61.7) 8 (21.1)
p value A 0.003 0.774
Argonaute 2 34 (100) 61 (100) 48 (100)
negative 27 (79.4) 21 (34.4) 15 (31.3)
positive 7 (20.6) 40 (65.6) 33 (68.8)
p value A <0.001 <0.001
Drosha 35 (100) 61 (100) 45 (100)
negative 23 (65.7) 8 (13.1) 23 (51.1)
positive 12 (34.3) 53 (86.9) 22 (48.9)
p value A <0.001 0.255
A Fisher’s exact test. (N)MIBC: (non-)muscle-invasive bladder cancer.
None of the three targets was associated with the clinicopathological parameters of age and
sex (Table 3). However, decreased expression of AGO1 (Chi-square test, p = 0.001) and Drosha
(Chi-square test, p < 0.001) was associated with advanced pathological tumor stage and with MIBC
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compared to NMIBC (Fisher’s exact test, p < 0.001) as mentioned above. Drosha levels were also
associated with World Health Organization (WHO) grade (Fisher’s exact test, p = 0.045). In order to
assess the consistency between AGO1, AGO2 and Drosha expression, the McNemar test was utilized.
We obtained significant differences between AGO1/AGO2 and AGO1/Drosha expression in bladder
tumor tissue samples (p < 0.001; Table 3).
Table 3. Immunostaining of AGO1, AGO2 and Drosha associated with clinicopathological parameters
of bladder cancer patients.
AGO1 n = 98 AGO2 n = 109 Drosha n = 106
Para-meters neg pos p value neg pos p value neg pos p value
n (%) 53 (54.1) 45 (45.9) 36 (33.0) 73 (67.0) 31 (29.2) 75 (70.8)
Age, years A
<69 23 (23.5) 21 (21.4) 0.839 B 17 (15.6) 33 (30.3) 1.000 B 15 (14.2) 36 (34.0) 1.000 B
≥69 30 (30.6) 24 (24.5) 19 (17.4) 40 (36.7) 16 (15.1) 39 (36.8)
Sex
female 14 (14.3) 12 (12.2) 1.000 B 10 (9.2) 20 (18.3) 1.000 B 8 (7.5) 22 (20.8) 0.815 B
male 39 (39.8) 33 (33.7) 26 (23.9) 53 (48.6) 23 (21.7) 53 (50.0)
pT stage
pTa 18 (18.4) 23 (23.5) 0.001 C 17 (15.6) 24 (22.0) 0.437 C 3 (2.8) 38 (35.8) <0.001 C
pT1 5 (5.1) 14 (14.3) 4 (3.7) 16 (14.7) 5 (4.7) 15 (14.2)
pT2 15 (15.3) 5 (5.1) 9 (8.3) 16 (14.7) 10 (9.4) 13 (12.3)
pT3 13 (13.3) 1 (1.0) 5 (4.6) 12 (11.0) 12 (11.3) 6 (5.7)
pT4 2 (2.0) 2 (2.0) 1 (0.9) 5 (4.6) 1 (0.9) 3 (2.8)
NMIBC 23 (23.5) 37 (37.8) <0.001 B 21 (19.3) 40 (36.7) 0.838 B 8 (7.5) 53 (50.0) <0.001 B
MIBC 30 (30.6) 8 (8.2) 15 (13.8) 33 (30.3) 23 (21.7) 22 (20.8)
WHO grade D
low 15 (15.3) 20 (20.4) 0.138 B 14 (12.8) 22 (20.2) 0.392 B 6 (5.7) 30 (28.3) 0.045 B
high 38 (38.8) 25 (25.5) 22 (20.2) 51 (46.8) 25 (23.6) 45 (42.5)
AGO1 E
neg - - - 21 (21.9) 31 (32.3) 0.025 B 22 (23.7) 27 (29.0) <0.001 B
pos - - - 8 (8.3) 36 (37.5) 5 (5.4) 39 (41.9)
AGO2 E
neg 21 (21.9) 8 (8.3) <0.001 F - - - 11 (10.7) 23 (22.3) 0.649 B
pos 31 (32.3) 36 (37.5) - - - 19 (18.4) 50 (48.5)
Drosha E
neg 22 (23.7) 5 (5.4) <0.001 F 11 (10.7) 19 (18.4) 0.644 F - - -
pos 27 (29.0) 39 (41.9) 23 (22.3) 50 (48.5) - - -
A Age was dichotomized according to median; B Fisher’s exact test (p < 0.05); C Chi-square test according to
Pearson (p < 0.05); D WHO/ISUP criteria of 2016; E number of valid cases: Ago1/Ago2 n = 96, Ago1/Drosha
n = 93, Ago2/Drosha n = 103; F McNemar test (p < 0.05). AGO: Argonaute; neg: negative, pos: positive staining;
(N)MIBC: (non-)muscle-invasive bladder cancer; WHO: World Health Organization; ISUP: International Society
of Uropathology.
2.3. Association of AGO1, AGO2 and Drosha Expression with Patient Survival
The overall survival times available for 110 cases were used in Kaplan–Meier survival analyses,
and different subgroups were compared using Chi-square and the log-rank tests. As expected,
higher pT stages and tumor grade were significantly associated with reduced patient survival
time (p < 0.001). We also obtained significant associations by performing separate Kaplan–Meier
analyses according to pTa and ≥pT1 tumors (p < 0.001) as well as for NMIBC and MIBC (p = 0.001).
In order to assess the clinical relevance of AGO1, AGO2 and Drosha as prognostic markers in bladder
cancer patients, the Kaplan–Meier analyses of dichotomized immunoreactivity data were conducted.
AGO1 and AGO2 expression levels that were divided into negative and positive values did not show
any significant differences for the available 96 cases and 107 cases, respectively (Figure 3A,B). However,
Drosha had a significant correlation with the overall survival time, with a higher probability of survival
associated with positive Drosha expression (73 cases, 20 events; 5-year survival of 73%) compared
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with negative expression (31 cases, 18 events; 5-year survival of 57%) (Figure 3C). Multivariate Cox
regression analysis including the clinicopathological parameters of age, sex, pT stage and tumor grade
combined with the three targets of AGO1, AGO2 and Drosha (alone or together) did not reveal any
statistical significances, while AGO1 turned out to be independent of all patient parameters (Table S1).
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3. Discussion
Nuclear cleavage of the primary miRNA by Drosha is an essential function in early miRNA
maturation. The proteins of the Argonaute family, AGO1 and AGO2, define the next step in miRNA
maturation in the cytoplasm and play a key role in post-transcriptional regulation, such as degrading
mRNA or impairing its translation. There is an increasing number of studies examining the implication
of miRNA maturation regulators in cancer pathobiology, whereas the contribution of Drosha and
Argonautes to the diagnosis and clinicopathological behavior of bladder cancer still needs to be
clarified. In this study, we investigated the immunohistochemical expression of Drosha, AGO1 and
AGO2 proteins in bladder cancer and their association with clinicopathological parameters and overall
survival in order to define the diagnostic and prognostic potentials of these miRNA processors for
bladder carcinoma.
Higher expression levels of AGO1 and AGO2 associated with tumor progression have been found
in different cancer entities, such as in epithelial skin cancer and ovarian cancer [14,15]. There was
an upregulation of AGO2 expression in an estrogen receptor α-negative breast cancer cell line,
in prostate cancer as well as in esophageal squamous cell carcinoma tissue, which indicates that AGO2
plays a key role in tumorigenesis [16,17]. Furthermore, in hematological cancers, such as multiple
myeloma, high AGO2 levels have been reported as a marker of high-risk disease [18]. With regard to
bladder carcinoma, previous studies have described the overexpression of Drosha, AGO1 and AGO2
compared to non-malignant bladder tissue [12,13], which we could attribute to NMIBC. In the case of
AGO2, this overexpression was found both in NMIBC and MIBC. The differentiation of NMIBC and
MIBC cases has not been considered in the earlier studies [12,13].
The association of AGO1 with AGO2 and Drosha according to our McNemar test hints at similar
processes and changes of miRNA machinery in bladder cancer, although AGO2 and Drosha were
different. With respect to clinicopathological parameters, we found decreased protein expression of
AGO1 and Drosha to be significantly associated with higher tumor stage and with MIBC in comparison
to NMIBC, although there were no differences for AGO2. In striking contrast, Yang et al. [12]
detected a significant association of increased AGO2 levels with higher histological grade, lymph
node metastasis and distant metastasis of bladder carcinoma. However, grade and statistical test were
not further defined in this study. Zhang et al. [13] claimed that higher AGO2 and Drosha expression
was associated with higher histological grade, pT stage (≥T1) and recurrence of bladder carcinoma,
although their table data indicated an association with lower grade. These results were inconsistent
and the grade was not further defined but we could confirm an association of higher Drosha levels
with the lower WHO grade according to criteria of 2016 if applicable to the study above. The decreased
expression of AGO1 and Drosha in MIBC compared with NMIBC could suggest a shift from more
active miRNA machinery to decreased activity. For bladder cancer, some increased oncogenic miRNAs
and many decreased tumor-suppressive miRNAs have been described [19] and thus, a connection
could be possible.
Higher Drosha [13] and AGO2 expressions [12,13] have been reported to correspond to shorter
overall survival [12] or to shorter recurrence-free and cancer-specific survival [13] in Kaplan–Meier
analysis although we only found Drosha to be significantly correlated with prolonged overall survival.
Yang et al. [12] contains very few cases in the Kaplan–Meier curves so that the results, especially
those indicating that AGO2 is an independent factor, are questionable. However, the other study [13]
presents enough cases for sound results and stresses AGO2 as an independent prognostic factor
in a reduced model with grade and pT stage only. We could not confirm the prognostic value
of AGO2 in our analyses, which had a median observation time of 53 months in contrast to the
36 months [12] and 35 months [13] of the other studies. In contrast, our calculations just proved
that AGO1 was independent of clinicopathological parameters, although AGO1 alone in univariate
analysis was not of any prognostic value, which was in contrast with Drosha. The significance in
the univariate analysis means that the variable can differentiate the lower and higher probability
of survival on its own, but the multivariate Cox regression will provide the quality of the variable
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compared with other (known) patient parameters. According to the Reporting Recommendations
for Tumor Marker Prognostic Studies (REMARK), which have been further explained in 2012 [20],
we included all variables available in multivariate analysis. Frequently, significant univariate variables
lack independence in the multivariate analysis, such as Drosha in our analysis, but there also are
variables which only show their quality in multivariate comparison, such as AGO1 in our study.
We could confirm the significance of AGO1 in the inclusion model in a backward Likelihood model
with the same parameters as in Table S1 (p = 0.018). We believe that the value of AGO1 as a prognostic
marker should be further evaluated.
Interestingly, in bladder tissue, we found that Drosha was not only present in nuclei, but also in
the cytoplasm, which seems contrary to its functional role in nuclear miRNA maturation regulation.
However, there are several reports on other tumor entities in which Drosha was observed in both
compartments, such as smooth muscle tumors, melanoma, esophageal and breast cancer [21–24].
The data on localization of Drosha and AGO1 in bladder tissue have been lacking until now because
Zhang et al. [13] did not present any in their study. We could confirm mainly the cytoplasmic
expression of AGO2 described by Yang et al. [12] but added some details on staining for all three
targets, such as the expression in endothelial cells or for AGO2 in lymphocytes, which should be taken
into consideration by certain measures, such as Western blot analyses.
As the antibodies used were different from ours (AGO2, [12]), or were not exactly described [13],
the difference in the results could have risen from different affinities or specificities, which accentuate
the limitations of immunohistochemical studies. Our antibodies were selected according to the
literature and were evaluated by an experienced pathologist (E.K.) to avoid artifacts. Another aspect is
the difference between our tissue and scoring system (tissue microarray, scoring by intensity) and those
of the other groups (full section per case, scoring by intensity and area) [12,13]; both have advantages
and disadvantages. For our microarray, we wanted to avoid any bias in an area score for little spots.
In histological tissue analysis, the quality of processed formalin-fixed and paraffin-embedded archival
material may also influence the staining intensity. In our explorative study, the number of events
analyzed was limited because of the limited number of investigated patients for whom comprehensive
data were available. This seems to be the main restriction of our work. Further studies are necessary
to elucidate the role of Drosha and AGOs in bladder cancer due to the shortcomings of the existing
contradictory data.
4. Materials and Methods
4.1. Tissue Sample Selection
A TMA composed of 112 human urothelial carcinomas of the bladder was used for our
retrospective study. Appropriate tissue was selected in accordance to availability and follow-up
data of the cases. The study was approved by the Ethics Committee of the HELIOS Hospital in
Bad Saarow, Germany (HRC-006913, 21, March, 2012), where all bladder cancer patients underwent
radical cystectomy (RTX) or transurethral resection (TUR-B) between 1999 and 2010. Written informed
consent was given according to the Declaration of Helsinki. In total, 85 TUR-B and 27 RTX were
carried out and none of the patients received any chemotherapy or radiation prior to surgery. For each
patient, the following clinical and pathological information was recorded: sex, age, tumor staging
according to the International Union Against Cancer, histological grading in accordance with the
WHO/ISUP criteria of 2016 and overall survival time in the months after surgery. An overview of
patient clinicopathological characteristics is given in Table 1.
The surgical specimens of normal adjacent urothelial and urothelial tumor tissue were fixed
in 4% buffered formaldehyde and embedded in paraffin. Histological diagnosis was established
on standard hematoxylin and eosin-stained sections by a pathologist. Tumor tissue samples were
subdivided into 62 NMIBC (pTa = 42 and pT1 = 20) and 50 MIBC tissue samples (pT2 = 26, pT3 = 18 and
pT4 = 6) according to the European Association of Urology guidelines, 2011 [25] (Table 1). Additionally,
Int. J. Mol. Sci. 2018, 19, 1622 10 of 12
the adjacent normal bladder tissues of 35 bladder tumor cases without any evidence for reactive
histology were included. Patients with carcinoma in situ or metastasis were excluded.
4.2. Construction of Tissue Microarray
The areas of bladder carcinoma and adjacent normal tissue were marked on 3-µm
hematoxylin/eosin (HE) stained sections of formalin-fixed paraffin-embedded tissue by a pathologist
(A.E.) at Charité-Universitätsmedizin Berlin, Germany. Of the corresponding blocks, cores were
punched out with a tissue arrayer (1.0 mm diameter; Beecher Instruments, Woodland, CA, USA)
according to the previously marked areas, which were subsequently embedded into a new paraffin
block as a TMA with maximal 125 cores per block and a tissue of at least 2 mm diameter. Histological
conformation was established on HE stained sections (A.E.) according to tumor staging and WHO
grading system of 2016.
4.3. Immunohistochemistry
Immunostaining was done as described previously [26]. The optimal concentration of the
primary antibody was determined in a dilution series on test sections of larger urothelial cancer
and corresponding adjacent normal tissue. Finally, the primary antibody against AGO1 (rabbit
monoclonal antibody, cat. no. 5053 [clone D84G10]; Cell Signaling Technology, Inc.; Boston, MA, USA)
was used at a dilution of 1:50 and incubated overnight at 4 ◦C. AGO2 (rabbit polyclonal antibody,
cat. no. ab32381; Abcam, Cambridge, UK) was used at a dilution of 1:50 and incubated for 1 h at
room temperature, while Drosha (rabbit polyclonal antibody, cat. no. ab12286, Abcam) was used
at a dilution of 1:250 and incubated for 1 h at room temperature in a humid chamber. Detection
was performed by conventional labeled streptavidin-biotin method with alkaline phosphatase as the
reporting enzyme. Fast-Red TR/Naphthol AS-MX (cat. no. F4648; Sigma-Aldrich, Munich, Germany)
was used as the chromogen. Finally, the TMA was counterstained with hematoxylin and fixed in
an aqueous embedding medium. Antibody diluent solution without the application of respective
primary antibodies was used as the negative control. Antibodies were checked by Western blotting
using the human urinary bladder carcinoma cell lines RT-4 and RT-112 (Figure S1). Immunostainings
were evaluated by a pathologist (E.K.) of Charité–Universitätsmedizin Berlin, who was blinded to the
clinicopathological data. Immunohistochemical expression of AGO1, AGO2 and Drosha was classified
in a binary manner from 0 to 1 according to the following assessment: 0 being no immunoreactivity;
and 1 being positive immunoreactivity with staining intensities including cytoplasmic and nuclear
staining. The number of assessable cases differed slightly between the three targets, because a few
tissue spots disappeared during the staining procedure.
4.4. Statistics
Statistical analyses were carried out with SPSS 21.0 (IBM Corp., Somers, NY, USA). Fisher’s
exact test, Chi-square test according to Pearson and McNemar test were applied to determine the
relationship between AGO1, AGO2 or Drosha immunostaining and clinicopathological characteristics.
Univariate analyses for the overall survival time as a function of AGO1, AGO2 or Drosha expression
were executed as Kaplan-Meier analyses using the log-rank test. The overall survival time as the
primary clinical endpoint was defined as the months elapsed between TUR-B or RTX and either
death or the last follow-up date. Multivariate analyses were calculated according to Cox regression.
Two-sided p-values < 0.05 were considered to be statistically significant in all cases.
5. Conclusions
In our study, the altered expressions of AGO1, AGO2, and Drosha were investigated
immunohistochemically in bladder cancer to evaluate their diagnostic and prognostic potential in
non-invasive and invasive bladder carcinoma. The upregulation of the targets and differentiation of
NMIBC and MIBC cases could improve diagnostics; additionally, AGO1 seems to hold prognostic
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potential for bladder cancer. However, our results stress the need for further research to bridge the gap
of prognostic markers in urothelial carcinomas of the bladder. Based on our results, we suggest that
Drosha and AGOs are important factors in the tumor biology of bladder cancer.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/19/6/
1622/s1.
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